Alnylam Pharmaceuticals Inc (ALNY)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
16/100
Low signalSIGNAL SCORE
P(beat S&P 500 · next 20 sessions)47%
Also measured against its sector ETF (XBI).
Our last 30 days of resolved calls came true 18% of the time.See the track record →
Price
$161.17
1 day
-2.34%
1 week
+5.38%
Month to date
+0.02%
1 year
-63.65%
Market cap
$22.1B
Company fundamentals
P/E (TTM)
8.1×
EPS (TTM)
$19.75
Debt / Equity
0.76
Current ratio
2.48
Operating margin
19.4%
Net margin
54.3%
Gross margin
77.3%
Return on equity
159.7%
Revenue growth (YoY)
56.2%
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
Example trade plan · illustrative risk framework
Entry zone
$158.75–$164.39
Stop-loss (exit)
$145.05 −10%
Target (exit)
$193.40 +20%
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
Why it ranks: factor attribution
- Weekly momentum+5.4% over the past week+6
- QualityRevenue growing 56% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →